Correction (Gastroenterology (2017) 152(1) (142–156.e2), (S0016508516350703), (10.1053/j.gastro.2016.09.009));Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications

Gastroenterology

Volumn 152, Issue 1, 2017, Pages 142-156.e2

  Nahon, Pierre ^a,b,c,ao   Bourcier, Valérie ^a   Layese, Richard ^d   Audureau, Etienne ^d   Cagnot, Carole ^e   Marcellin, Patrick ^f,ao   Guyader, Dominique ^g,ao   Fontaine, Hélène ^h,ao   Larrey, Dominique ^i,ao   De Lédinghen, Victor ^j,ao   Ouzan, Denis ^k,ao   Zoulim, Fabien ^l,ao   Roulot, Dominique ^m,ao   Tran, Albert ^n,o,ao   Bronowicki, Jean Pierre ^p,ao   Zarski, Jean Pierre ^q,ao   Leroy, Vincent ^q,ao   Riachi, Ghassan ^r,ao   Calès, Paul ^s,ao   Péron, Jean Marie ^t,ao   Alric, Laurent ^u,ao   Bourlière, Marc ^v,ao   Mathurin, Philippe ^w,ao   Dharancy, Sébastien ^w   Blanc, Jean Frédéric ^x,ao   Abergel, Armand ^y,ao   Serfaty, Lawrence ^z,ao   Mallat, Ariane ^d,ao   Grangé, Jean Didier ^aa,ao   Attali, Pierre ^ab,ao   Bacq, Yannick ^ac,ao   Wartelle, Claire ^ad,ao   Dao, Thông ^ae,ao   Benhamou, Yves ^h,ao   Pilette, Christophe ^af,ao   Silvain, Christine ^ag,ao   Christidis, Christos ^ah,ao   Capron, Dominique ^ai,ao   Bernard Chabert, Brigitte ^aj   Zucman, David ^ak   Di Martino, Vincent ^al,ao   Thibaut, Vincent ^g   Salmon, Dominique ^am   Ziol, Marianne ^a,b,c,an   Sutton, Angela ^a,b,an   Pol, Stanislas ^c,h,ao   Roudot Thoraval, Françoise ^d   Thiefin, Gérard ^ao   Hillaire, Sophie ^ao   more..

^a HÔPITAL JEAN VERDIER   (France)

^b UNIVERSITÉ PARIS 13   (France)

^c INSERM   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e Unit for Basic and Clinical Research on Viral Hepatitis   (France)

^f BEAUJON HOSPITAL   (France)

^g PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^h ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

ⁱ HÔPITAL SAINT ELOI   (France)

^j HAUT LÉVÊQUE HOSPITAL   (France)

^k INSTITUT ARNAULT TZANCK   (France)

^l UNIVERSITÉ DE LYON   (France)

^m AVICENNE HOSPITAL   (France)

ⁿ UNIVERSITY HOSPITAL OF NICE   (France)

^o CENTRE MÉDITERRANÉEN DE MÉDECINE MOLÉCULAIRE C3M   (France)

^p UNIVERSITY HOSPITAL OF NANCY   (France)

^q HÔPITAL MICHALLON   (France)

^r HÔPITAL CHARLES NICOLLE   (France)

^s ANGERS UNIVERSITY HOSPITAL   (France)

^t CHU PURPAN   (France)

^u TOULOUSE UNIVERSITY HOSPITAL   (France)

^v HÔPITAL SAINT JOSEPH   (France)

^w LILLE UNIVERSITY HOSPITAL   (France)

^x HÔPITAL SAINT ANDRÉ   (France)

^y HÔTEL DIEU   (France)

^z HÔPITAL SAINT ANTOINE   (France)

^aa HÔPITAL TENON   (France)

^ab HÔPITAL PAUL BROUSSE   (France)

^ac SERVICE DE DERMATOLOGIE   (France)

^ad Hôpital d'Aix en Provence   (France)

^ae CHU CÔTE DE NACRE   (France)

^af Centre Hospitalo Universitaire Le Mans   (France)

^ag POITIERS UNIVERSITY HOSPITAL   (France)

^ah INSTITUT MUTUALISTE MONTSOURIS   (France)

^ai AMIENS UNIVERSITY HOSPITAL   (France)

^aj SERVICE DE DERMATOLOGIE   (France)

^ak FOCH HOSPITAL   (France)

^al UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^am NONE   (France)

^an Centre de Ressources Biologiques   (France)

^ao NONE

more..

Author keywords

ANRS CirVir; Direct Antivirals; HCV Clearance; Prognosis

Indexed keywords

ANTIVIRUS AGENT; BOCEPREVIR; PEGINTERFERON; RIBAVIRIN; SOFOSBUVIR; TELAPREVIR; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; ASCITES; BACTERIAL INFECTION; BILE DUCT CARCINOMA; CANCER INCIDENCE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHILD PUGH SCORE; COHORT ANALYSIS; COMORBIDITY; COMPENSATED LIVER CIRRHOSIS; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; LIVER CELL CARCINOMA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK REDUCTION; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; TREATMENT INDICATION; VIRAL CLEARANCE; AGED; BACTERIAL INFECTIONS; BLOOD; BODY MASS; CARCINOMA, HEPATOCELLULAR; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES MELLITUS; DYSLIPIDEMIAS; FRANCE; INCIDENCE; LIVER CIRRHOSIS; LIVER NEOPLASMS; PATHOPHYSIOLOGY; PROTHROMBIN TIME; THROMBOCYTE COUNT;

AGED; ANTIVIRAL AGENTS; ASPARTATE AMINOTRANSFERASES; BACTERIAL INFECTIONS; BODY MASS INDEX; CARCINOMA, HEPATOCELLULAR; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; DYSLIPIDEMIAS; FEMALE; FOLLOW-UP STUDIES; FRANCE; GAMMA-GLUTAMYLTRANSFERASE; HEPATITIS C; HUMANS; INCIDENCE; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PLATELET COUNT; PROSPECTIVE STUDIES; PROTHROMBIN TIME; SUSTAINED VIROLOGIC RESPONSE;

EID: 85006295141     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2019.02.029     Document Type: Erratum

References (39)

1. 1 Webster, D.P., Klenerman, P., Dusheiko, G.M., Hepatitis C. Lancet 385 (2015), 1124–1135.
2. 2 Sangiovanni, A., Prati, G.M., Fasani, P., et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology 43 (2006), 1303–1310.
3. 3 Negro, F., Forton, D., Craxi, A., et al. Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology 149 (2015), 1345–1360.
4. 4 Jepsen, P., Vilstrup, H., Lash, T.L., Development and validation of a comorbidity scoring system for patients with cirrhosis. Gastroenterology 146 (2014), 147–156 quiz e15–e16.
5. 5 Innes, H.A., McDonald, S.A., Dillon, J.F., et al. Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes. Hepatology 62 (2015), 355–364.
6. 6 van der Meer, A.J., Veldt, B.J., Feld, J.J., et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308 (2012), 2584–2593.
7. 7 Morgan, R.L., Baack, B., Smith, B.D., et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 158 (2013), 329–337.
8. 8 Bruno, S., Shiffman, M.L., Roberts, S.K., et al. Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology 51 (2010), 388–397.
9. 9 Hsu, Y.C., Ho, H.J., Huang, Y.T., et al. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut 64 (2015), 495–503.
10. 10 Jepsen, P., Vilstrup, H., Andersen, P.K., The clinical course of cirrhosis: the importance of multistate models and competing risks analysis. Hepatology 62 (2015), 292–302.
11. 11 Lau, B., Cole, S.R., Gange, S.J., Competing risk regression models for epidemiologic data. Am J Epidemiol 170 (2009), 244–256.
12. 12 O'Malley, K.J., Cook, K.F., Price, M.D., et al. Measuring diagnoses: ICD code accuracy. Health Serv Res 40 (2005), 1620–1639.
13. 13 Brennan, T., Shrank, W., New expensive treatments for hepatitis C infection. JAMA 312 (2014), 593–594.
14. 14 Nahon, P., Lescat, M., Layese, R., et al. Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort). Gut, 2015 Epub ahead of print. http://dx.xoi.org/10.1136/gutjnl-2015-310275.
15. 15 Trinchet, J.C., Bourcier, V., Chaffaut, C., et al. Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort). Hepatology 62 (2015), 737–750.
16. 16 von Elm, E., Altman, D.G., Egger, M., et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370 (2007), 1453–1457.
17. 17 Bruix, J., Sherman, M., Management of hepatocellular carcinoma. Hepatology 42 (2005), 1208–1236.
18. 18 Bruix, J., Sherman, M., Management of hepatocellular carcinoma: an update. Hepatology 53 (2011), 1020–1022.
19. 19 de Franchis, R., Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 53 (2010), 762–768.
20. 20 European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 53 (2010), 397–417.
21. 21 Fernandez, J., Acevedo, J., Castro, M., et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology 55 (2012), 1551–1561.
22. 22 Lavoie, L., Khoury, H., Welner, S., et al. Burden and prevention of adverse cardiac events in patients with concomitant chronic heart failure and coronary artery disease: a literature review. Cardiovasc Ther 34 (2016), 152–160.
23. 23 Sarrazin, C., Hezode, C., Zeuzem, S., et al. Antiviral strategies in hepatitis C virus infection. J Hepatol 56:Suppl 1 (2012), S88–S100.
24. 24 Austin, P.C., Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 10 (2011), 150–161.
25. 25 Normand, S.T., Landrum, M.B., Guadagnoli, E., et al. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. J Clin Epidemiol 54 (2001), 387–398.
26. 26 Kabiri, M., Jazwinski, A.B., Roberts, M.S., et al. The changing burden of hepatitis C virus infection in the United States: model-based predictions. Ann Intern Med 161 (2014), 170–180.
27. 27 European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 60 (2014), 392–420.
28. 28 N'Kontchou, G., Paries, J., Htar, M.T., et al. Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis. Clin Gastroenterol Hepatol 4 (2006), 1062–1068.
29. 29 Reau, N.S., Jensen, D.M., Sticker shock and the price of new therapies for hepatitis C: is it worth it?. Hepatology 59 (2014), 1246–1249.
30. 30 Arvaniti, V., D'Amico, G., Fede, G., et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 139 (2010), 1246–1256 1256.e1–1256.e5.
31. 31 Jalan, R., Fernandez, J., Wiest, R., et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol 60 (2014), 1310–1324.
32. 32 Vanni, E., Abate, M.L., Gentilcore, E., et al. Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. Hepatology 50 (2009), 697–706.
33. 33 Petta, S., Macaluso, F.S., Craxi, A., Cardiovascular diseases and HCV infection: a simple association or more?. Gut 63 (2014), 369–375.
34. 34 Lee, M.H., Yang, H.I., Lu, S.N., et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 206 (2012), 469–477.
35. 35 Petta, S., Torres, D., Fazio, G., et al. Carotid atherosclerosis and chronic hepatitis C: a prospective study of risk associations. Hepatology 55 (2012), 1317–1323.
36. 36 Maruyama, S., Koda, M., Oyake, N., et al. Myocardial injury in patients with chronic hepatitis C infection. J Hepatol 58 (2013), 11–15.
37. 37 Boddi, M., Abbate, R., Chellini, B., et al. Hepatitis C virus RNA localization in human carotid plaques. J Clin Virol 47 (2010), 72–75.
38. 38 Innes, H., Goldberg, D., Dillon, J., et al. Strategies for the treatment of hepatitis C in an era of interferon-free therapies: what public health outcomes do we value most?. Gut 64 (2015), 1800–1809.
39. 39 Innes, H.A., Hutchinson, S.J., Allen, S., et al. Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care. Hepatology 54 (2011), 1547–1558.